ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 185

Distribution of Haemochromatosis Arthropathy. High Ankle and Mid Foot Prevalence; A Diagnostic Clue ?

Patrick Kiely1 and Alex Richardson2, 1Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, 2Rheumatology, St George's Healthcare NHS Trust, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankle, diagnosis and hemochromatosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose . Long delays in diagnosis of haemochromatosis are frequent and lead to an adverse affect on hepatic and cardiac outcome. Arthropathy is a highly prevalent and early feature, which could act as a trigger for diagnosis if sufficiently distinctive. We conducted a survey of patients with haemochromatosis to assess the prevalence and distribution of joint symptoms and their relation to the diagnosis.

Methods . A questionnaire was sent to members of the UK Haemochromatosis Society (~1500) in December 2013. Questions assessed how the diagnosis of haemochromatosis was made; symptoms, duration, the prevalence and distribution of affected joints, and the role of a rheumatologist.

Results . Questionnaires were returned by 470 people with haemochromatosis, 97% white, 53% male. The genotype was C282Y homozygous 52%, C282Y/H63D heterozygous 7%, C282Y/wild type heterozygous 5%, unknown 33%. The diagnosis was made at a mean age of 56 years, following family member screening in 20%, well man/woman screening in 23% and as result of symptoms in 57%. At diagnosis the most frequent symptoms attributed to haemochromatosis were fatigue 65% and joint pain 60% (Fig 1), with a mean duration of 8 years (0-65) and mean Ferritin 1752 mg/L.  The diagnosis was most frequently made by a GP 38%, Haematologist 24%, Gastroenterologist 21.5% and Rheumatologist 7%.

88% of respondents reported joint pain, stiffness or swelling. Joint symptoms preceded the diagnosis of haemochromatosis by more than 5 years in 47%, by more than 1 year in 78.5% and post dated the diagnosis in 14.5%. The most prevalent areas affected were hand or wrist 66%, ankle or mid foot 49%, and knee 44% (Fig 2). In the hands the prevalence of symptoms was 1st CMC 60%, wrist 52%, MCP 47%, PIP 48%, and DIP joints 41%. No formal arthritic diagnosis was given to 45%, OA 29%, haemochromatosis arthropathy 11.5%. Dupuytrens disease was reported by 13% of men and 8% of women. Venesection was reported to have helped joint symptoms in 5%, made no impact in 20% and in 51% new joints had become affected following de ironing. A negative impact on employment from arthropathy was reported by 21%, with 9% losing their job.

Conclusion . In haemochromatosis, joint symptoms are highly prevalent at diagnosis, with the ankle and mid foot involved in 49%. In addition to MCP joint disease, an osteoarthritis-like presentation at a relatively young age in the hind or mid foot might be a distinguishing feature to prompt investigations leading to an earlier diagnosis.  

Figure 1 Symptoms at diagnosis

Figure 2 Distribution of joint symptoms


Disclosure:

P. Kiely,
None;

A. Richardson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distribution-of-haemochromatosis-arthropathy-high-ankle-and-mid-foot-prevalence-a-diagnostic-clue/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology